Get the Stockscreener App
30.11
2.28%
0.67
After Hours:
29.88
-0.23
-0.76%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $30.11, with a volume of 34.23M.
It is up +2.28% in the last 24 hours and up +8.86% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$29.44
Open:
$29.67
24h Volume:
34.23M
Relative Volume:
1.14
Market Cap:
$171.62B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
23.09
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
+6.13%
1M Performance:
+8.86%
6M Performance:
+9.41%
1Y Performance:
+21.95%
1-Day Range:
$29.59
$30.25
1-Week Range:
$29.25
$30.25
52-Week Range:
$23.62
$30.25
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
30.11 | 171.62B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,283.66 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.36 | 625.03B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
289.08 | 510.84B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.30 | 365.88B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.64 | 292.03B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-06-26 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-10-26 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Wells Fargo keeps Hold on Pfizer stock. It gains 1.03 percent - ad-hoc-news.de
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally? - The Motley Fool
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch - Yahoo Finance
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch - Zacks Investment Research
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? - Zacks Investment Research
Is Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now? - Zacks Investment Research
Key facts: Pfizer Inc. expands oncology tie-up; raises dividend $0.43 - TradingView
Can Pfizer’s (NYSE:PFE) Earnings Support Its NYSE Composite Position? - Kalkine Media
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? - The Motley Fool
Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year - The Motley Fool
Micro Pfizer Inc Stock Futures, (XPFE0H27.CME) interactive stock chart - Yahoo Finance UK
Micro Pfizer Inc Stock Futures, (XPFE0H27.CME) latest stock news and headlines - Yahoo Finance UK
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline - The Motley Fool
PFIZER INC (PFE-USD.SW) cash flow - Yahoo Finance UK
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Pfizer Inc. (PFE.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pfizer Inc. Research & Ratings | PFE - Barron's
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends - The Motley Fool
Pfizer Inc. Stock Grades | PFE - Barron's
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe? - The Motley Fool
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? - Yahoo Finance
What to Expect From Pfizer's Q3 2026 Earnings Report - Yahoo Finance
Lilly, Pfizer, J&J win EU drug recommendations this month - Seeking Alpha
PFIZER INC. R (PFE.DE) Q1 FY2025 earnings call transcript - Yahoo Finance
Layoffs Tracker: Kroger, Pfizer, Netflix and Amazon Hit This Week - Yahoo Finance
6 Blue Chip Stocks Trading Well Below Their Highs - The Motley Fool
Pfizer Inc. (PFE) latest press releases and corporate news - Yahoo Finance Australia
2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends - The Motley Fool
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Pfizer Stock Hits 52-Week High: What's Going On? - Benzinga
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Pfizer stock hits 52-week high at $29.88 - Investing.com
The Pfizer Foundation and the American Red Cross: Strengthening Communities Year-Round - American Red Cross
Pfizer, Thermo Fisher Scientific And More: CNBC’s ‘Final Trades’ - Benzinga
PFIZER INC (PFE-USD.SW) recent insider transactions - Yahoo Finance UK
PFIZER INC (PFE-USD.SW) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Pfizer Inc (Coinbase Tokenized Stock) Price | PFEc Price Today, Live Chart, USD converter, Market Capitalization - CryptoRank
Pfizer (NYSE:PFE): What Changes After Its Latest Company Update? - Kalkine Media
Pfizer (PFE) Gains As Market Dips: What You Should Know - Zacks Investment Research
Pfizer (PFE) Gains As Market Dips: What You Should Know - Yahoo Finance
Micro Pfizer Inc Stock Futures, (XPFE0Z26.CME) Stock Historical Prices & DataYahoo Finance - Yahoo! Finance Canada
Micro Pfizer Inc Stock Futures, (XPFE0Z26.CME) latest stock news and headlines - Yahoo Finance UK
Pfizer Inc Stock (PFE) Moved Up by 3.14% on Oct 14: Drivers Behind the Movement - TradingKey
Pfizer cuts another 150 jobs at Portage plant as demand slips - Crain's Grand Rapids Business
Pfizer’s Next‑Gen Pneumococcal Shot Enters Key Phase 3 Test, Extending Vaccine Growth Potential - TipRanks
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pfizer Inc Stock (PFE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DAMICO JENNIFER B. | SVP & Controller |
Aug 05 '26 |
Sale |
25.40 |
3,278 |
83,261 |
28,611 |
| BLAYLOCK RONALD E | Director |
Aug 05 '26 |
Buy |
25.46 |
39,231 |
998,821 |
66,938 |
| Buckley Mortimer J | Director |
Aug 05 '26 |
Buy |
25.52 |
37,632 |
960,369 |
37,632 |
| DAMICO JENNIFER B. | SVP & Controller |
Jun 09 '26 |
Sale |
25.70 |
2,000 |
51,400 |
31,397 |
| SAHNI PAYAL | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
82,816 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
2.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):